A current study is investigating the role of sodium‐glucose transporter 2 (SGLT‐2) inhibitor therapy in the treatment of heart failure in patients with and without diabetes mellitus with the use of MEMRI (NCT04591639). This evidence concerns the gene SLC5A2 and heart failure.